Novo Nordisk Scores Hemophilia Win but Stumbles on Obesity Device as Buyback and India Launch Provide Counterweight
Published on 07/12/2026 at 06:12 | Redaktion boerse-global.de
Novo Nordisk’s stock has clawed back more than 40% from its March nadir, yet the Danish drugmaker’s latest week was a study in contrasts. A promising readout for its experimental hemophilia A candidate Denecimig and the commercial rollout of a once-weekly insulin in India were balanced by the quiet withdrawal of a Phase 2 obesity device study, all while a massive buyback programme continues to steady the ship. The B-share closed Friday at €43.32, up 1.29% on the day, though the seven-day performance eked out only a 0.41% decline as the equity consolidates after a sharp rebound.
Positive data from the FRONTIER4 Phase 3 extension trial landed on July 11 at the International Society on Thrombosis and Haemostasis congress in Paris. The interim analysis covered 426 patients aged one year and older — 365 adolescents and adults with a median observation of six months, and 61 children tracked for a median of four months. Denecimig (Mim8), administered subcutaneously once monthly, every two weeks, or weekly, showed a safety profile consistent with earlier studies. Injection-site reactions were rare: 2.0% of injections in children and 1.8% in adolescents and adults, all mild and transient. Martin Holst Lange, head of R&D, said the data confirm Denecimig’s potential as a prophylactic treatment regardless of inhibitor status or dosing frequency. The drug is already under review by the U.S. Food and Drug Administration following a submission earlier this year. While Denecimig remains a small piece of Novo Nordisk’s diversification beyond its GLP-1 core, the FRONTIER4 results strengthen the hemophilia franchise alongside the established Alhemo.
Less visible but noteworthy was the withdrawal of a Phase 2 study for CagriSema, a candidate targeting type-2 diabetes and obesity. The trial, officially pulled on July 7, was designed to compare two different injection systems for the combination therapy. Analysts view the move as a manageable risk — it does not directly threaten near-term revenue from the current GLP-1 portfolio — but it casts a shadow over the company’s device strategy for the next generation of obesity treatments. The focus may now shift to other Phase 3 programmes, leaving competitors more breathing room in the obesity space.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
On the commercial front, Novo Nordisk continued its push into emerging markets by launching Awiqli, its once-weekly basal insulin, in India this week. The product reduces the required injections from 365 to 52 per year compared with daily alternatives, a meaningful convenience for patients. India becomes the seventh country to roll out Awiqli, and with roughly six million people currently on insulin therapy there — a figure expected to climb to nine million — the opportunity is substantial.
The dominant force behind the stock’s recent resilience, however, remains the aggressive buyback programme. Since February 4, 2026, Novo Nordisk has repurchased 23,009,179 B-shares up to July 3 at an average price of DKK 270.32, for a total outlay of over €830 million. The broader plan authorizes up to DKK 15 billion in buybacks over twelve months from February 2026, with a tranche launched in May targeting as much as DKK 11.2 billion through early February 2027. The company now holds 40,194,480 own B-shares, equivalent to 0.9% of share capital. HSBC lifted its price target from DKK 280 to DKK 300 at the start of July, though it retained a “hold” rating.
Technically, the stock remains 29% below its 52-week high of €61.20 set in July 2025, but has climbed more than 43% from the March trough of €30.25. It now trades above both its 50-day moving average of €39.51 and its 200-day moving average of €40.60, while the 14-day relative strength index at 66 points to a rally that is extended but not yet overbought. Year-to-date, the shares are still down roughly 3%.
The half-year results, expected in the coming weeks, will be the real test. They will reveal whether the recent recovery reflects genuine operational improvement or is largely a technical lift from buyback demand and short-covering. Until then, Novo Nordisk’s equity remains caught between the structural support of its own repurchases and lingering questions about the next chapter of its obesity pipeline.
Ad
Novo Nordisk Stock: New Analysis - 12 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
